Erenumab meets endpoint in Phase III migraine trial
Positive top-line results for erenumab from a global Phase III, randomized, double-blind, placebo-controlled STudy to evaluate the efficacy and safety of erenumab in migRaIne preVEntion (STRIVE) have been released.
According to US biotech Amgen (Nasdaq: AMGN) and Swiss pharma giant Novartis (NOVN: VX), who are partnering on the development of erenumab (AMG 334), these data showed the STRIVE study met the primary endpoint, demonstrating statistically-significant reductions from baseline in monthly migraine days in patients with episodic migraine treated with either 70mg or 140mg erenumab compared with placebo. Erenumab is specifically designed to prevent migraine by blocking the calcitonin gene-related peptide (CGRP) receptor, which is believed to have a critical role in mediating the incapacitating pain of migraine.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze